|
US5571787A
(en)
|
1993-07-30 |
1996-11-05 |
Myelos Corporation |
Prosaposin as a neurotrophic factor
|
|
US5700909A
(en)
*
|
1993-07-30 |
1997-12-23 |
The Regents Of The University Of California |
Prosaposin and cytokine-derived peptides
|
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US5861499A
(en)
|
1994-02-10 |
1999-01-19 |
Imclone Systems Incorporated |
Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
|
|
US5840301A
(en)
*
|
1994-02-10 |
1998-11-24 |
Imclone Systems Incorporated |
Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
|
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
|
GB9825632D0
(en)
*
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
|
FR2793691B1
(fr)
*
|
1999-05-21 |
2003-10-03 |
Hippocampe |
Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
|
|
GB0007911D0
(en)
*
|
2000-03-30 |
2000-05-17 |
Novartis Ag |
Organic compounds
|
|
CN100553636C
(zh)
|
2000-08-04 |
2009-10-28 |
Dmi生物科学公司 |
二酮基哌嗪和包含它们的组合物的使用方法
|
|
ME00502B
(me)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antitjela za insulinu sličan receptor faktora i rasta
|
|
WO2002085924A2
(en)
*
|
2001-04-23 |
2002-10-31 |
Abgenix, Inc. |
ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE
|
|
EP2295081B1
(de)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Antikörper gegen OPGL
|
|
AR037456A1
(es)
|
2001-11-30 |
2004-11-10 |
Biogen Inc |
Anticuerpos contra proteinas quimiotacticas monocitarias
|
|
PT1527100E
(pt)
*
|
2002-03-29 |
2009-08-25 |
Schering Corp |
Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
|
|
MX352180B
(es)
|
2002-04-09 |
2017-11-13 |
Biogen Ma Inc |
El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
|
|
AU2002368055B2
(en)
*
|
2002-06-28 |
2008-09-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
|
|
ES2346868T3
(es)
*
|
2002-08-10 |
2010-10-21 |
Yale University |
Antagonistas de receptor nogo.
|
|
WO2004030522A2
(en)
*
|
2002-10-02 |
2004-04-15 |
Dmi Biosciences, Inc. |
Diagnosis and monitoring of diseases
|
|
EP1460088A1
(de)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
|
|
EA009643B1
(ru)
*
|
2003-04-16 |
2008-02-28 |
Йейл Юниверсити |
Лечение состояний, включающих амилоидные бляшки
|
|
AU2004234364A1
(en)
*
|
2003-04-24 |
2004-11-11 |
Lisette Acevedo |
Nogo-B, a regulator of endothelial cell function and vessel remodeling
|
|
EP2517718B1
(de)
|
2003-05-15 |
2016-03-02 |
Ampio Pharmaceuticals, Inc. |
Behandlung von T-Zell-vermittelten Krankheiten
|
|
MX370489B
(es)
*
|
2004-01-09 |
2019-12-16 |
Pfizer |
Anticuerpos contra madcam.
|
|
CN101072797B
(zh)
|
2004-03-12 |
2012-05-09 |
瓦斯基因治疗公司 |
结合ephb4、抑制血管发生和肿瘤生长的抗体
|
|
US7280939B2
(en)
*
|
2004-04-29 |
2007-10-09 |
International Business Machines Corporation |
System and method of analyzing timing effects of spatial distribution in circuits
|
|
KR20080019733A
(ko)
*
|
2004-07-16 |
2008-03-04 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
|
WO2006037604A1
(en)
*
|
2004-10-01 |
2006-04-13 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel antibodies directed to the mammalian eag1 ion channel protein
|
|
CN101102791B
(zh)
|
2004-11-18 |
2011-12-14 |
英克隆有限责任公司 |
抗血管内皮生长因子受体-1的抗体
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
CA2601400A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
JP5225069B2
(ja)
|
2005-03-23 |
2013-07-03 |
ゲンマブ エー／エス |
多発性骨髄腫の治療のためのｃｄ３８に対する抗体
|
|
US20090053229A1
(en)
*
|
2005-05-12 |
2009-02-26 |
Lee Daniel H S |
Methods of Treating Conditions Involving Neuronal Degeneration
|
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
PT1981902E
(pt)
|
2006-01-27 |
2015-11-02 |
Biogen Ma Inc |
Antagonistas dos recetores nogo
|
|
JP2007284415A
(ja)
*
|
2006-03-10 |
2007-11-01 |
Daicel Chem Ind Ltd |
アミド又はラクタムの製造法
|
|
AU2007240732B2
(en)
*
|
2006-04-21 |
2013-07-04 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
|
MX2008015830A
(es)
|
2006-06-30 |
2009-01-09 |
Novo Nordisk As |
Anticuerpos anti-nkg2a y usos de los mismos.
|
|
WO2008033333A2
(en)
|
2006-09-08 |
2008-03-20 |
Amgen Inc. |
Il-1 family variants
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
WO2008037257A2
(en)
|
2006-09-26 |
2008-04-03 |
Genmab A/S |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
|
TW200831129A
(en)
*
|
2006-10-06 |
2008-08-01 |
Amgen Inc |
Stable formulations
|
|
EP2094247B1
(de)
*
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stabile polypeptid-formulierungen
|
|
EP2094733A1
(de)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4-antikörper
|
|
CA2790018C
(en)
*
|
2006-12-21 |
2015-02-03 |
Amgen Inc. |
Formulations
|
|
SG178744A1
(en)
|
2007-02-02 |
2012-03-29 |
Biogen Idec Inc |
Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
|
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
|
EP2014681A1
(de)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
JP5769969B2
(ja)
|
2007-11-12 |
2015-08-26 |
ユー３・ファーマ・ゲーエムベーハー |
Ａｘｌ抗体
|
|
AU2008337517B2
(en)
|
2007-12-14 |
2014-06-26 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
|
KR20100110864A
(ko)
|
2008-01-24 |
2010-10-13 |
노보 노르디스크 에이/에스 |
인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
|
|
RU2540013C2
(ru)
*
|
2008-03-13 |
2015-01-27 |
Биотест Аг |
Средство для лечения заболевания
|
|
EP2260057B1
(de)
*
|
2008-03-13 |
2016-11-23 |
Biotest AG |
Anti-CD4 Antikörper Dosierungsschema zur Behandlung von Autoimmunkrankheiten
|
|
EP2265643B1
(de)
*
|
2008-03-13 |
2016-10-19 |
Biotest AG |
Dosierungsschema zur behandlung von psoriasis und rheumatoider arthritis
|
|
JP5856843B2
(ja)
|
2008-05-27 |
2016-02-10 |
アンピオ ファーマシューティカルズ，インコーポレイテッド |
ジケトピペラジンを用いた医薬組成物
|
|
RU2011111391A
(ru)
*
|
2008-08-28 |
2012-10-10 |
Эбботт Байотерапьютикс Корп. (Us) |
Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
|
|
BRPI0919489A2
(pt)
*
|
2008-09-29 |
2015-12-01 |
Biotest Ag |
composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato
|
|
EP2172485A1
(de)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
CN103382222B
(zh)
|
2009-03-20 |
2016-12-28 |
安姆根有限公司 |
α-4-β-7异二聚体特异性拮抗剂抗体
|
|
EP2246364A1
(de)
*
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Antikörper gegen CXCR4 zur Behandlung von HIV
|
|
EA022788B1
(ru)
|
2009-07-03 |
2016-03-31 |
Бионор Иммуно Ас |
Новые терапевтические и диагностические средства
|
|
MX2012001283A
(es)
|
2009-07-31 |
2012-06-12 |
Amgen Inc |
Polipeptidos que se enlazan al inhibidor de tejidos de metaloproteinasa tipo tres (timp-3) composiciones y metodos.
|
|
EP2308897A1
(de)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
|
|
MX340971B
(es)
|
2009-11-23 |
2016-08-02 |
Amgen Inc * |
Fragmento cristalizable (fc) de anticuerpo monomerico.
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
EP2371863A1
(de)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
CN103429739B
(zh)
|
2010-05-12 |
2018-11-13 |
哥伦比亚大学纽约管理委员会 |
制备产生和分泌胰岛素的肠内分泌细胞的方法
|
|
WO2012012141A1
(en)
|
2010-06-30 |
2012-01-26 |
Amgen Inc. |
Scnn1a/tnfrsf1a fusion proteins in cancer
|
|
SG187867A1
(en)
|
2010-08-16 |
2013-03-28 |
Amgen Inc |
Antibodies that bind myostatin, compositions and methods
|
|
EP2613786A4
(de)
|
2010-09-07 |
2013-10-23 |
Dmi Acquisition Corp |
Behandlung von erkrankungen
|
|
EP2640745B1
(de)
|
2010-09-10 |
2018-11-07 |
MedImmune Limited |
Bivalente und bispezifische antikörper gegen il-6 und il-23
|
|
CA2814908A1
(en)
|
2010-10-27 |
2012-05-03 |
Pierre Fabre Medicament |
Antibodies for the treatment of hiv
|
|
MX2013008833A
(es)
|
2011-02-02 |
2013-12-06 |
Amgen Inc |
Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
MY172699A
(en)
|
2011-10-10 |
2019-12-10 |
Ampio Pharmaceuticals Inc |
Implantable medical devices with increased immune tolerance, and methods for making and implanting
|
|
EA028343B1
(ru)
|
2011-10-10 |
2017-11-30 |
Ампио Фармасьютикалз, Инк. |
Лечение дегенеративного заболевания сустава
|
|
EA201992617A1
(ru)
|
2011-10-26 |
2020-03-10 |
Амген Инк. |
Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
|
|
EP2771007B1
(de)
|
2011-10-28 |
2018-04-04 |
Ampio Pharmaceuticals, Inc. |
Behandlung von rhinitis
|
|
EP2589609A1
(de)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
|
|
EP2793947B1
(de)
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatische konjugation von polypeptiden
|
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
|
US9441039B2
(en)
|
2012-05-07 |
2016-09-13 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
AU2013266069B2
(en)
|
2012-05-25 |
2018-03-15 |
Sloan Kettering Institute For Cancer Research |
Methods for treating GI syndrome and graft versus host disease
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
AU2013273481B2
(en)
|
2012-06-06 |
2018-04-05 |
Bionor Immuno As |
HIV vaccine
|
|
CN105050618B
(zh)
|
2012-06-21 |
2018-11-16 |
索伦托治疗有限公司 |
与c-Met结合的抗原结合蛋白
|
|
WO2013192596A2
(en)
|
2012-06-22 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind ccr2
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014022102A1
(en)
|
2012-08-01 |
2014-02-06 |
Amgen Inc. |
Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture
|
|
PL2914630T3
(pl)
|
2012-11-05 |
2021-09-06 |
Pierre Fabre Médicament |
Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
|
|
EP3564259A3
(de)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Kennungen für tgase-vermittelte konjugation
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
|
EP2970451A1
(de)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1-antigenbindende proteine und behandlungsmethoden damit
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
BR112015020469A2
(pt)
|
2013-03-15 |
2020-01-28 |
Ampio Pharmaceuticals Inc |
Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
|
|
EP3010547B1
(de)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatische konjugation von polypeptiden
|
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
EP3041863A4
(de)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
|
|
UA125204C2
(uk)
|
2013-09-05 |
2022-02-02 |
Аб2 Біо Са |
Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
|
|
WO2015036956A1
(en)
|
2013-09-12 |
2015-03-19 |
Institut National De La Sante Et De La Recherche Medicale |
Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
|
|
RS66894B1
(sr)
|
2013-10-31 |
2025-07-31 |
Amgen Inc |
Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina
|
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
|
WO2015116315A1
(en)
|
2014-01-29 |
2015-08-06 |
Amgen Inc. |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
|
DK3134438T3
(da)
|
2014-04-25 |
2020-12-07 |
Pf Medicament |
IGF-1R-antistof og anvendelse heraf som adresseringsvehikel til behandling af cancer
|
|
HUE047952T2
(hu)
|
2014-04-25 |
2020-05-28 |
Pf Medicament |
Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
|
|
HRP20190888T8
(hr)
|
2014-04-25 |
2019-10-04 |
Pierre Fabre Médicament |
Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
|
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
|
RU2736513C2
(ru)
|
2014-08-18 |
2020-11-17 |
Ампио Фармасьютикалз, Инк. |
Лечение патологических состояний суставов
|
|
EA201790437A1
(ru)
|
2014-08-22 |
2017-08-31 |
Сорренто Терапьютикс, Инк. |
Антигенсвязывающие белки, связывающиеся с cxcr3
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
CA2961950A1
(en)
|
2014-09-28 |
2016-03-31 |
The Regents Of The University Of California |
Modulation of stimulatory and non-stimulatory myeloid cells
|
|
AU2015331602A1
(en)
|
2014-10-17 |
2017-04-27 |
Amgen Inc. |
Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
|
|
EP3256165B1
(de)
|
2015-02-13 |
2021-07-14 |
Sorrento Therapeutics, Inc. |
Antikörpertherapeutika mit bindung von ctla4
|
|
US10882905B2
(en)
|
2015-03-05 |
2021-01-05 |
Ab2 Bio Sa |
IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
|
|
US10214591B1
(en)
|
2015-04-03 |
2019-02-26 |
Alienor Farma |
Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
|
US9951144B2
(en)
|
2015-04-08 |
2018-04-24 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD38
|
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
|
EP3310375A4
(de)
|
2015-06-22 |
2019-02-20 |
Ampio Pharmaceuticals, Inc. |
Verwendung von niedermolekularen fraktionen von humanem serumalbumin bei der behandlung von erkrankungen
|
|
EP3356415B1
(de)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr-inhibitoren
|
|
KR20180105634A
(ko)
|
2015-10-26 |
2018-09-28 |
피에르 파브르 메디카먼트 |
Igf-1r을 발현하는 암의 치료를 위한 조성물
|
|
ES3015244T3
(en)
|
2015-12-31 |
2025-04-30 |
Ecs Progastrin Sa |
Compositions and methods for detecting and treating ovarian cancer
|
|
KR102477179B1
(ko)
|
2015-12-31 |
2022-12-13 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
위암의 검출 및 치료를 위한 조성물 및 방법
|
|
KR102197478B1
(ko)
|
2015-12-31 |
2021-01-04 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
식도암을 검출 및 치료하기 위한 조성물 및 방법
|
|
WO2017132562A1
(en)
|
2016-01-29 |
2017-08-03 |
Heyue Zhou |
Antigen binding proteins that bind pd-l1
|
|
WO2017153432A1
(en)
|
2016-03-07 |
2017-09-14 |
Pierre Fabre Medicament |
A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
|
JP6972022B2
(ja)
|
2016-05-11 |
2021-11-24 |
アムジエン・インコーポレーテツド |
グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
|
|
MA45595A
(fr)
|
2016-07-07 |
2019-05-15 |
Iovance Biotherapeutics Inc |
Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018144784A1
(en)
|
2017-02-01 |
2018-08-09 |
Smet Pharmaceutical Inc. |
MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
|
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
|
SG11201908996YA
(en)
|
2017-03-30 |
2019-10-30 |
Ecs Progastrin Sa |
Compositions and methods for detecting lung cancer
|
|
KR102317805B1
(ko)
|
2017-03-30 |
2021-10-27 |
이씨에스-프로가스트린 에스에이 |
전립선암을 검출하기 위한 조성물 및 방법
|
|
EP3652211A1
(de)
|
2017-07-14 |
2020-05-20 |
Pfizer Inc. |
Antikörper gegen madcam
|
|
EP3444272A1
(de)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
|
|
US20210332141A1
(en)
|
2017-08-30 |
2021-10-28 |
Amgen Inc. |
Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use
|
|
WO2019110662A1
(en)
|
2017-12-05 |
2019-06-13 |
Progastrine Et Cancers S.À R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ｅｃｓ前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
|
EP3759492A1
(de)
|
2018-02-27 |
2021-01-06 |
ECS-Progastrin SA |
Progastrin als biomarker für immuntherapie
|
|
US20210355199A1
(en)
|
2018-06-28 |
2021-11-18 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
|
|
EP3856258B1
(de)
|
2018-09-27 |
2024-07-31 |
Pierre Fabre Medicament |
Sulfomaleimidbasierte linker und zugehörige konjugate
|
|
MX2021003580A
(es)
|
2018-09-28 |
2021-10-13 |
Pf Medicament |
Nuevas inmunocitocinas para el tratamiento contra el cancer.
|
|
TWI840433B
(zh)
|
2018-10-29 |
2024-05-01 |
大陸商北京強新生物科技有限公司 |
新穎合理設計的蛋白質組合物
|
|
JP7725066B2
(ja)
|
2019-04-18 |
2025-08-19 |
キューエルエスエフ バイオセラピューティック インコーポレイテッド |
ヒト化抗ｐｄ－ｌ１抗体
|
|
US12404331B2
(en)
|
2019-04-19 |
2025-09-02 |
Tcrcure Biopharma Corp. |
Anti-PD-1 antibodies and uses thereof
|
|
CN113728003A
(zh)
|
2019-04-30 |
2021-11-30 |
吉加根公司 |
重组多克隆蛋白及其使用方法
|
|
WO2020231629A1
(en)
|
2019-05-16 |
2020-11-19 |
Snake River Bioscience, Inc. |
Compositions and methods for the treatment of major depressive disorder
|
|
MA56110A
(fr)
|
2019-06-07 |
2022-04-13 |
Amgen Inc |
Constructions de liaison bispécifiques à lieurs clivables de manière sélective
|
|
US20210221886A1
(en)
|
2019-12-05 |
2021-07-22 |
Sorrento Therapeutics, Inc. |
Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
|
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
|
CA3168986A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
WO2021195089A1
(en)
|
2020-03-23 |
2021-09-30 |
Sorrento Therapeutics, Inc. |
Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
|
|
EP3889183A1
(de)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
Proteinkomplex mit einem immunzytokin
|
|
CN115943310A
(zh)
|
2020-04-24 |
2023-04-07 |
索伦托药业有限公司 |
用于检测抗sars-cov-2中和抗体的侧向流动装置
|
|
EP4139345A1
(de)
|
2020-04-24 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Dimere gedächtnis-antigenrezeptoren
|
|
JP2023525060A
(ja)
|
2020-05-14 |
2023-06-14 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
|
|
EP4161969A1
(de)
|
2020-06-04 |
2023-04-12 |
Amgen Inc. |
Bispezifische bindungskonstrukte
|
|
WO2021253002A1
(en)
|
2020-06-12 |
2021-12-16 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
|
|
JP2023532279A
(ja)
|
2020-06-26 |
2023-07-27 |
ソレント・セラピューティクス・インコーポレイテッド |
免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
|
|
US20230235059A1
(en)
|
2020-06-26 |
2023-07-27 |
Sorrento Therapeutics, Inc. |
Anti-pd1 antibodies and uses thereof
|
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
|
|
CN117280211A
(zh)
|
2020-11-04 |
2023-12-22 |
索伦托药业有限公司 |
用于冠状病毒感染的高灵敏度检测的侧向流动装置及其制造和使用方法
|
|
US20250277024A1
(en)
|
2020-12-03 |
2025-09-04 |
Amgen Inc. |
Molecules with multiple binding domains
|
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
|
JP2024513172A
(ja)
|
2021-03-26 |
2024-03-22 |
ヤンセン バイオテツク，インコーポレーテツド |
対らせん状細線維タウに対するヒト化抗体及びその使用
|
|
WO2022261262A1
(en)
|
2021-06-09 |
2022-12-15 |
Sorrento Therapeutics, Inc. |
Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
|
|
US20240279321A1
(en)
|
2021-06-18 |
2024-08-22 |
Therini Bio, Inc. |
ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
|
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對ｉｇｆ—培養基之適應
|
|
EP4489790A1
(de)
|
2022-03-10 |
2025-01-15 |
Vivasor, Inc. |
Antikörper-wirkstoff-konjugate und verwendungen davon
|
|
CN119173531A
(zh)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
多特异性抗体及其用途
|
|
AU2023232448A1
(en)
|
2022-03-11 |
2024-10-24 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
CA3254442A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
AU2024221322A1
(en)
|
2023-02-17 |
2025-07-03 |
Apogee Therapeutics, Inc. |
Antibodies that bind interleukin 4 receptor alpha and methods of use
|
|
CN121969398A
(zh)
|
2023-04-05 |
2026-05-01 |
维硕公司 |
抗体偶联药物及其用途
|
|
CN121969397A
(zh)
|
2023-04-05 |
2026-05-01 |
维硕公司 |
抗体偶联药物及其用途
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
AU2024294028A1
(en)
|
2023-07-11 |
2026-01-22 |
Amgen Inc. |
Alternating recirculating tangential flow (artf) filtration for cell culture media perfusion and bioreactor harvesting
|
|
US20250027052A1
(en)
|
2023-07-21 |
2025-01-23 |
Amgen Inc. |
Vectors incorporating a combination of promoters driving selectable marker expression
|
|
WO2025038732A1
(en)
|
2023-08-15 |
2025-02-20 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
|
|
AU2024363859A1
(en)
|
2023-10-18 |
2026-04-09 |
Amgen Inc. |
Evaluation of mrna transcript levels using ddpcr for early pool and single-cell clone assessment in cell line development
|
|
WO2025137523A2
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical formulations of antibodies that bind interleukin 13
|
|
WO2025137410A1
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
|
|
WO2025155774A2
(en)
|
2024-01-19 |
2025-07-24 |
Amgen Inc. |
Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
|
|
WO2025155776A1
(en)
|
2024-01-19 |
2025-07-24 |
Amgen Inc. |
Expression vector systems with two copies of light chain
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
WO2025184493A1
(en)
|
2024-02-29 |
2025-09-04 |
Amgen Inc. |
Dual selection expression vector systems for multi-chain biologics
|
|
CN121175334A
(zh)
|
2024-04-13 |
2025-12-19 |
益免安协公司 |
在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法
|
|
WO2025255353A1
(en)
|
2024-06-06 |
2025-12-11 |
Apogee Therapeutics, Inc. |
Dosage and administration of an anti-ox40l antibody
|
|
WO2026019782A2
(en)
|
2024-07-16 |
2026-01-22 |
Amgen Inc. |
Methods for reducing filter fouling in perfusion cell cultures with recirculating tangential flow filtration
|
|
WO2026024904A1
(en)
|
2024-07-24 |
2026-01-29 |
Gigagen, Inc. |
Custom recombinant polyclonal proteins and methods of use thereof
|
|
WO2026080829A1
(en)
|
2024-10-10 |
2026-04-16 |
Apogee Therapeutics, Inc. |
Methods of administering antibodies that bind interleukin 13
|
|
WO2026085417A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
|
|
WO2026085419A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
|